Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Molecular and Clinical Oncology|December 25, 2024
Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer painYoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2021
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancerShinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, et al.
Cancer Research|June 7, 2015
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Junko Tanizaki, Dalia Ercan, Marzia Capelletti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation-Positive Non-Small Cell Lung CancerKohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, et al.
Cancer Science|October 27, 2021
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019LShinya Sakata, Kohei Otsubo, Hisako Yoshida, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2025
Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)Taiki Hakozaki, Kentaro Tanaka, Yoshimasa Shiraishi, et al.
Thoracic Cancer|February 13, 2025
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene TestingNaoki Shiraishi, Takayuki Takahama, Kazuko Sakai, et al.
Cancer Research|April 2, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsTakayuki Kosaka, Junko Tanizaki, Raymond M Paranal, et al.
Pageof 7